Ivermectin can kill cancer cells in laboratory dishes and shrink tumors in mice, but there is no evidence it works as a cancer treatment in humans. No clinical trial has demonstrated that ivermectin helps people with cancer, and the FDA has not approved it for any oncology use. The drug remains approved only for treating certain parasitic infections.
That said, the lab findings are genuinely interesting, and researchers have explored ivermectin as a potential drug to repurpose for cancer. Here’s what the science actually shows and where it falls short.
What Lab Studies Have Found
In cell cultures, ivermectin interferes with several signaling pathways that cancer cells rely on to grow and survive. It blocks a pathway called Wnt that colorectal cancer cells use to proliferate, and it disrupts another growth-signaling chain (Akt/mTOR) in glioma cells. It also inhibits a protein called PAK1 that plays a role in several tumor types, with a better safety profile than other PAK1-blocking compounds tested so far.
One particularly striking finding involves cancer stem cells, the small subset of tumor cells thought to drive regrowth and treatment resistance. In triple-negative breast cancer cells, ivermectin preferentially killed these stem-like cells while leaving more of the regular tumor cells intact. Standard chemotherapy with paclitaxel showed the opposite pattern, killing bulk tumor cells but sparing the stem-like ones. Ivermectin also reduced the expression of genes tied to self-renewal by up to 80-100% at low concentrations, and cut the formation of tumor-seeding cell clusters by up to 73%.
In mice with breast cancer tumors, ivermectin reduced tumor volume by up to 60%. A study on pancreatic cancer found that combining ivermectin with gemcitabine (a standard chemotherapy drug) suppressed tumor growth significantly more than gemcitabine alone. The combination triggered cancer cell death more effectively, disrupted the cells’ energy production, and halted cell division at an earlier stage.
The Lab-to-Human Problem
The concentrations needed to kill cancer cells in a dish are the central issue. In colorectal cancer cell lines, the amount of ivermectin required to kill half the cancer cells ranged from about 6 to 16 micromolar, depending on the cell type and exposure time. For breast cancer cells, activity was seen in the 0.2 to 8 micromolar range. These are concentrations that may be difficult or impossible to achieve safely in human blood.
The FDA-approved dose for parasitic infections is up to 200 micrograms per kilogram of body weight. A safety study in healthy adults tested doses up to 10 times that amount and found no significant increase in side effects compared to placebo, with no signs of nervous system toxicity. That’s reassuring for safety at higher doses, but it doesn’t confirm those doses produce blood levels high enough to affect tumors the way researchers see in lab experiments.
There’s also a drug interaction concern that cuts both ways. Ivermectin could potentially speed up the body’s clearance of chemotherapy drugs, reducing their effectiveness. Or it could slow clearance down, amplifying toxicity. Case reports from around the world have flagged unexpected side effects when ivermectin is combined with other medications, making the interaction unpredictable without controlled study.
Where Human Trials Stand
The clinical trial picture is thin. A Phase II trial was planned to test ivermectin combined with an immunotherapy drug for metastatic triple-negative breast cancer, but it was withdrawn before enrolling patients. No completed human trial has demonstrated that ivermectin improves cancer outcomes.
This is the gap that matters most. Thousands of compounds kill cancer cells in a dish. The vast majority fail when tested in people, because the human body processes drugs differently than isolated cells do, because tumors in living tissue behave differently than cells on a plate, and because side effects at effective doses can be intolerable. Ivermectin has not yet crossed any of these hurdles for cancer.
Why Researchers Are Still Interested
Despite the lack of human evidence, ivermectin has qualities that make it attractive for further study. It’s inexpensive, widely available, and has decades of safety data at standard doses. Its ability to target cancer stem cells rather than just bulk tumor cells is unusual and potentially valuable, since cancer stem cells are thought to be responsible for relapse after treatment. And its synergy with existing chemotherapy drugs in animal models suggests it might eventually find a role as an add-on therapy rather than a standalone treatment.
Some researchers have argued that ivermectin’s anticancer effects may be achievable at “clinically feasible” blood concentrations, meaning levels that could realistically be reached in patients. But this remains a hypothesis supported by mouse data, not human results.
What This Means in Practice
Ivermectin is not a cancer treatment. It is not recommended by any oncology organization for any cancer type. A 2025 review on ivermectin and gynecologic cancers put it bluntly: the safety and efficacy of ivermectin in cancer is unknown and unsupported, and its use outside of a clinical trial is not evidence-based.
The biological mechanisms are real, the lab results are consistent across multiple cancer types, and the drug’s safety profile makes it a reasonable candidate for further research. But “kills cancer cells in a lab” is the earliest possible stage of drug development, and most drugs that reach this stage never become cancer treatments. Until human trials produce results, ivermectin’s anticancer potential remains exactly that: potential.